Becton, Dickinson and Company

Core Business

Becton, Dickinson and Company (BD) is the world's foremost manufacturer of injection and infusion consumables, generating over 23 billion USD in annual revenue. Following the strategic separation of its Biosciences & Diagnostic Solutions business to Waters Corporation in February 2026, BD has transformed into a pure-play medical technology manufacturer focused exclusively on medical consumables, vascular access devices, and pharmacy automation systems. BD's core manufacturing competencies center on precision needle grinding and cannula extrusion, medical-grade polymer injection molding, and automated assembly of sterile disposable devices. The company's syringe, IV catheter, and blood collection consumable lines represent the world's highest-volume production operations in their respective categories, with billions of units manufactured annually across 16 dedicated manufacturing sites.

Global Presence

BD operates a strategically distributed global manufacturing network comprising 16 world-class manufacturing facilities located in the United States, Mexico, Ireland, China, India, and Singapore. The company maintains particularly deep manufacturing localization in China, with three major production plants in Suzhou and Yixing alongside a dedicated Greater China R&D center, supporting annual China revenue exceeding 1 billion USD under its "In China, for China" strategy. BD's manufacturing excellence is founded on proprietary metal cannula processing technology—combining high-speed needle grinding, siliconization coating, and automated hub bonding—that has been refined over 125+ years of continuous manufacturing operations.

Key Strengths

BD's fundamental competitive moat lies in the irreplaceable manufacturing precision and at-scale production economics of its core consumable lines. The company's syringe manufacturing operations achieve unit costs that cannot be replicated by smaller competitors due to the enormous capital investment in high-speed automated production lines and proprietary needle-point grinding technology. BD's recent strategic pivot to a pure-play MedTech manufacturer—following the 2026 diagnostics business separation—enables sharper management focus and capital allocation toward consumable manufacturing excellence. The company's deep China manufacturing localization provides resilience against trade-related supply chain disruption while serving the world's second-largest healthcare market. Primary risks include post-spinoff integration complexity and exposure to China's centralized volume-based procurement (VBP) pricing pressure on commoditized injection and infusion consumables.

VerityRank Score

Based on comprehensive evaluation of global injection consumable production dominance, precision manufacturing technology depth, production volume scale, and strategic positioning as a pure-play MedTech manufacturer, BD achieves a VerityRank Score of 89/100. The company's 125+ year manufacturing heritage, unrivaled syringe and IV catheter production volumes, and post-spinoff strategic clarity establish an enduring competitive position in the global medical consumable manufacturing landscape.